[1]王任飞,田小丽,谭建,等.腰椎能谱CT评估Graves甲状腺功能亢进症患者131I治疗前后骨量变化的价值[J].国际放射医学核医学杂志,2018,(6):495-499,506.[doi:10.3760/cma.j.issn.1673-4114.2018.06.004]
　Wang Renfei,Tian Xiaoli,Tan Jian,et al.Changes of bone mass in patients with Graves’ hyperthyroidism before and after 131I therapy based on CT spectral imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):495-499,506.[doi:10.3760/cma.j.issn.1673-4114.2018.06.004]
点击复制

腰椎能谱CT评估Graves甲状腺功能亢进症患者131I治疗前后骨量变化的价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第6期
页码:
495-499,506
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Changes of bone mass in patients with Graves’ hyperthyroidism before and after 131I therapy based on CT spectral imaging
作者:
王任飞;  田小丽;  谭建;  张桂芝;  张瑞国;  何雅静
300052, 天津医科大学总医院核医学科
Author(s):
Wang Renfei;  Tian Xiaoli;  Tan Jian;  Zhang Guizhi;  Zhang Ruiguo;  He Yajing
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
格雷夫斯病; 甲状腺功能亢进; 体层摄影术; X线计算机; 碘放射性同位素; 骨量; 放射性核素治疗
Keywords:
Graves disease; Hyperthyroidism; Tomograp;  X-ray computed; Bone mass; Radionuclide therapy; Iodine Radioisotopes
DOI:
10.3760/cma.j.issn.1673-4114.2018.06.004
摘要:
目的 探讨能谱CT成像对Graves甲状腺功能亢进症（简称甲亢）患者骨量评估的价值，以及131I治疗对Graves甲亢患者骨量的影响。方法 收集2015年6月至10月期间在我科接受131I治疗的68例Graves甲亢患者[（男性13例、女性55例，年龄（40.6±10.7）岁]，治疗前采用双能X线吸收法（DXA）测定腰椎骨密度（BMD），能谱CT测定第3腰椎钙（水）密度，采用Pearson相关分析及线性回归探讨二者的相关性。治疗后半年随访评价疗效，复查腰椎能谱CT，采用配对t检验比较131I治疗前后骨量变化。结果 DXA的测定结果显示，68例Graves甲亢患者中有21例伴有骨量减少（30.9%），7例伴有骨质疏松（10.3%）。骨量正常组患者的第3腰椎钙（水）密度为（64.33±14.65）g/cm3，骨量减少组为（48.29±4.45）g/cm3，而骨质疏松组为（41.65±1.21）g/cm3，3组间差异有统计学意义（χ2=35.811，P<0.001）。骨量正常组患者的第3腰椎BMD为（1.252±0.305）g/cm2，骨量减少组为（1.103±0.254）g/cm2，而骨质疏松组为（0.539±0.066）g/cm2，3组间差异有统计学意义（F=12.968，P<0.001）。Graves甲亢患者的第3腰椎钙（水）密度与DXA测定的腰椎BMD呈高度正相关（r=0.794，假设检验水准α=0.01，t=10.605，P<0.001）。由线性回归分析得到线性回归方程：第3腰椎钙（水）密度=24.485+34.529腰椎BMD。治疗后半年随访发现，甲亢治愈组患者131I治疗后腰椎钙（水）密度较治疗前增加，骨量改善，差异有统计学意义（t=7.86，P<0.001）；而甲亢未愈组患者较治疗前变化不显著，差异无统计学意义（t=2.29，P=0.062）。结论 能谱CT测得的腰椎钙（水）密度可用于评估Graves甲亢患者的骨量。患者经131I治疗后，骨量可随着甲亢的有效缓解而显著改善。
Abstract:
Objective To investigate the value of CT spectral imaging to evaluate bone mass in patients with Graves’ hyperthyroidism, and the changes of bone mass before and after 131I therapy. Methods Sixty-eight patients(13 males, 55 females; age 40.6±10.7yr) with Graves’ hyperthyroidism who received 131I therapy from June to October 2015 were involved in our study. The bone mineral density(BMD) of lumbar was obtained by dual energy X-ray absorptiometry(DXA), and the calcium-water concentration of L3 was measured by CT spectral imaging before 131I therapy. Pearson correlation analysis and linear regression were performed to explore the relationship between them. All clinical data were collected to assess the efficacy of 131I therapy after 6 months. CT spectral imaging was repeated, in order to compare the changes of bone mass using comparative t-test. Results Of these patients with Graves’ hyperthyroidism, 30.9% (21/68) patients with osteopenia and 10.3%(7/68) patients with osteoporosis were diagnosed according to the results of BMD by DXA. The calcium (water) densities of L3 were (64.33±14.65), (48.29±4.45) and (41.65±1.21) g/cm3 in patients with normal bone mass, bone loss and osteoporosis, respectively. The differences between the three groups were statistically significant (χ2=35.811, P<0.001). The bone mineral density of L3 were (1.252±0.305), (1.103±0.254) and (0.539±0.066) g/cm3 in patients with normal bone mass, bone loss and osteoporosis, respectively. The differences between the three groups were statistically significant (F=12.968, P<0.001). The calcium-water concentrations of L3 (g/cm3) were highly correlated with BMD values (g/cm2) of lumbar determined by DXA(r=0.794, hypothesis testing standard α=0.01, t=10.605, P<0.001). Equation of linear regression:the calcium-water concentration of L3=24.485+34.529 BMD value of lumbar. Furthermore, after 131I therapy, the calcium-water concentrations of L3 increased(t=7.86, P<0.001) in the cured group of patients. But there weren’t significant difference in the uncured group of patients(t=2.29, P=0.062). Conclusions CT spectral imaging can be used to evaluate bone mass in patients with Graves’ hyperthyroidism. Bone mass can be improved with remission of hyperthyroidism after 131I therapy.

参考文献/References:

[1] 高继兵, 蔡善武, 黄海泉, 等. 甲亢131Ⅰ治疗前后骨密度及相关指标变化分析[J].中华核医学杂志, 2005, 25(4):237-239. Gao JB, Cai SW, Huang HQ, et al. Changes of bone mineral density and related parameters in patients of hyperthyroidism before and after 131I therapy[J]. Chin J Nucl Med, 2005, 25(4):237-239.
[2] El MA, Roux C. DXA scanning in clinical practice[J]. QJM, 2008, 101(8):605-617. DOI:10.1093/qjmed/hcn022.
[3] Karabulut O, Tuncer MC, Karabulut Z, et al. Relationship between radiographic features and bone mineral density in elder men[J]. Folia Morphol (Warsz), 2010, 69(3):170-176.
[4] 陈靖, 郑邵微, 苗延巍, 等. 能谱CT定量钙(水)密度技术对腰椎椎体内及椎体间骨密度差异的研究[J]. 大连医科大学学报,2015, 37(3):289-292. DOI:10.11724/jdmu.2015.03.21. Chen J, Zheng SW, Miao YW, et al. Intra and inter vertebral calcium(water) density variation measured by Gemstone Spectral Imaging[J]. J Dalian Med Univ, 2015, 37(3):289-292. DOI:10.11724/jdmu.2015.03.21. DOI:10.11724/jdmu.2015.03.21.
[5] 蒋宁一, 匡安仁, 谭建, 等. 131I治疗Graves甲亢专家共识[J]. 中华核医学与分子影像杂志, 2010, 30(5):346-351. DOI:10.3760/cma.j.issn.0253-9780.2010.05.019. Jiang NY, Kuang AR, Tan J, et al. Expert consensus for 131I treatment of Graves hyperthyroidism[J]. Chin J Nucl Med Mol Imaging, 2010, 30(5):346-351.DOI:10.3760/cma.j.issn.0253-9780.2010.05.019.
[6] 袁园, 卫红艳, 刘萍, 等. 甲状腺功能亢进对骨代谢影响[J]. 临床荟萃, 2012, 27(3):206-209. Yuan Y, Wei HY, Liu P, et al. Effect of hyperthyroidism on bone metabolism[J]. Clin Focus, 2012, 27(3):206-209.
[7] 蒋宁一, 林岩松, 关海霞, 等. 131I治疗格雷夫斯甲亢指南[J]. 中华核医学与分子影像杂志, 2013, 33(2):83-95. DOI:10.3760/cma.j.issn.2095-2848.2013.02.002. Jiang NY, Lin YS, Guan HX, et al. Clinical guidelines for 131I treatment of Graves hyperthyroidism[J]. Chin J Nucl Med Mol Imaging, 2013, 33(2):83-95. DOI:10.3760/cma.j.issn.2095-2848. 2013.02.002.
[8] 邱明琪, 胡美华. 甲状腺功能亢进症患者骨密度变化的临床分析[J]. 实用临床医学, 2012, 13(6):16-17, 20. DOI:10.3969/j.issn.1009-8194.2012.06.006. Qiu MQ, Hu MH. Bone mineral density in patients with hyperthyroidism[J]. Pract Clin Med, 2012, 13(6):16-17, 20. DOI:10.3969/j.issn.1009-8194.2012.06.006.
[9] Dhanwal DK. Thyroid disorders and bone mineral metabolism[J]. Indian J Endocrinol Metab, 2011, 15(Suppl 2):S107-112. DOI:10.4103/2230-8210.83339.
[10] Gorka J, Taylor-Gjevre RM, Arnason T. Metabolic and clinical consequences of hyperthyroidism on bone density[J/OL]. Int J Endocrinol, 2013, 2013:638727[2018-03-07]. https://www.ncbi.nlm.nih.gov/pubmed/23970897. DOI:10.1155/2013/638727.
[11] Tuchendler D, Bolanowski M. The influence of thyroid dysfunction on bone metabolism[J]. Thyroid Res, 2014, 7(1):12. DOI:10.1186/s13044-014-0012-0.
[12] 王勇, 丁勇, 邢家骝, 等. 甲状腺功能亢进患者131碘治疗前后骨密度的变化[J]. 临床荟萃, 2015, 30(1):74-77. DOI:10.3969/j.issn.1004-583X.2015.01.020. Wang Y, Ding Y, Xing J L, et al. Bone mineral density change in hyperthyroidism patients before and after 131I treatment[J]. Clin Focus, 2015(1):74-77. DOI:10.3969/j.issn.1004-583X.2015. 01.020.
[13] 张红, 叶爱玲, 廖二元. 女性甲状腺功能亢进症患者的骨密度变化[J]. 中南大学学报(医学版), 2008, 33(5):452-455. DOI:10.3321/j.issn:1672-7347.2008.05.015. Zhang H, Ye AL, Liao EY. Change in bone mineral density in female patients with hyperthyroidism[J]. J Cent South Univ (Med Sci), 2008, 33(5):452-455. DOI:10.3321/j.issn:1672-7347. 2008. 05.015.
[14] 陈靖, 董越, 葛莹, 等. 探讨能谱CT宝石能谱成像技术用于骨密度测量的可行性[J]. 中国医学影像技术, 2013, 29(1):133-137. Chen J, Dong Y, Ge Y, et al. Feasibility of bone density measurement based on CT gemstone spectral imaging[J]. Chin J Med Imaging Technol, 2013, 29(1):133-137.
[15] Grampps S. Radiology of osteoporosis[M]. Berlin:Springer, 2008:163-173.
[16] 张昕, 王峻, 苏晋生, 等. 定量CT与双能X线吸收测定仪测量腰椎各椎体间骨密度差异性研究[J].中国医学影像学杂志, 2011, 19(12):884-886, 930. DOI:10.3969/j.issn.1005-5185. 2011. 12.002. Zhang X, Wang J, Su JS, et al. Differences of BMD betweenlumbar vertebrae measured by QCT and DXA[J]. Chin J Med Imaging, 2011, 19(12):884-886, 930. DOI:10.3969/j.issn.1005-5185. 2011. 12.002.
[17] Anderson NG, Butler AP. Clinical applications of spectral molecular imaging:potential and challenges[J]. Contrast Media Mol Imaging, 2014, 9(1):3-12. DOI:10.1002/cmmi.1550.
[18] Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis[J]. Thyroid, 2003,13(6):585-593. DOI:10.1089/105072503322238854.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[6]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[7]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[8]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
　Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[9]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[10]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]

备注/Memo

备注/Memo:
收稿日期:2018-03-08。
基金项目:国家自然科学基金青年科学基金（81501510）
通讯作者:谭建,Email:tanpost@163.com
更新日期/Last Update: 2018-12-31